Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Operating Leases (2019 - 2025)

Acro Biomedical has reported Operating Leases over the past 7 years, most recently at $13651.0 for Q2 2025.

  • Quarterly results put Operating Leases at $13651.0 for Q2 2025, down 65.66% from a year ago — trailing twelve months through Jun 2025 was $13651.0 (down 65.66% YoY), and the annual figure for FY2024 was $26898.0, changed 0.0%.
  • Operating Leases for Q2 2025 was $13651.0 at Acro Biomedical, down from $18009.0 in the prior quarter.
  • Over the last five years, Operating Leases for ACBM hit a ceiling of $39755.0 in Q2 2024 and a floor of $5888.0 in Q3 2021.
  • Median Operating Leases over the past 5 years was $19385.0 (2022), compared with a mean of $20290.6.
  • Biggest five-year swings in Operating Leases: tumbled 66.79% in 2021 and later skyrocketed 214.29% in 2022.
  • Acro Biomedical's Operating Leases stood at $25719.0 in 2021, then changed by 0.0% to $25719.0 in 2022, then increased by 4.58% to $26898.0 in 2023, then changed by 0.0% to $26898.0 in 2024, then tumbled by 49.25% to $13651.0 in 2025.
  • The last three reported values for Operating Leases were $13651.0 (Q2 2025), $18009.0 (Q1 2025), and $26898.0 (Q4 2024) per Business Quant data.